Under an agreement with Abbott (ABT), Qiagen (QGEN) will receive test kits for a molecular test of HIV in the US and Canada. The test, to be commercialized under Qiagen’s brand, is expected to be available by 2012. In addition, Qiagen will receive a quantitative HCV test which will be used on its QIAsymphony RGQ instrument.
However, the test, to be marketed under Abbott’s brand, is yet to receive regulatory approval. Earlier, in September, Qiagen had launched the QIAsymphony RGQ instrument to address the fast growing molecular diagnostics market.
On the other hand, Qiagen will supply Abbott some of the key products for a HPV test which will run on the latter’s m2000 lab automation system. However, financial details of the deal were not disclosed.
Qiagen’s portfolio consists of several tests catering to a wide patient base. In July, 2010, the company received CE Mark approval for its care HPV test. The certification implies that the test has met the required norms in the EU thereby, enabling the company to distribute the test in developing regions that recognize the CE Mark.
As a result, the company will be able to target the developing regions of India and Africa where there is high prevalence of cervical cancer. While cervical cancer causes nearly 274,000 deaths every year, 88% happen in developing countries.
Qiagen’s portfolio of HPV tests consists of digene HPV test which is considered to be the most efficient and effective solution for laboratory-based testing. The care HVT test makes the process simpler, effective and affordable for women in developing regions. This test has other advantages as well. It can be performed even without electricity or running water and detection results can be made available within a few hours.
We believe the deal should enable both the companies to further strengthen their positions in the field of in-vitro diagnostic applications. According to estimates, annual sales of HIV and HCV tests in the US market are approximately $180 million and $140 million, respectively. Consequently, a huge potential exists in these markets.
ABBOTT LABS (ABT): Free Stock Analysis Report
QIAGEN NV (QGEN): Free Stock Analysis Report
Zacks Investment Research
